{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57","upperLimit":"86","value":"70"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"41","value":"16"},{"groupId":"OG002","lowerLimit":"51","upperLimit":"79","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"description":"PFS is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 28 weeks. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \\>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.","dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG000","title":"Cohort A: MSI Positive Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG001","title":"Cohort B: MSI Negative Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG002","title":"Cohort C: MSI Positive Non-Colorectal Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 weeks","title":"Progression Free Survival (PFS) at 28 Weeks in MSI Positive and Negative Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}